Intravenous Immunoglobulins in Complex-regional Pain Syndrome
Stopped: No more interest to follow this study
Germany0Started 2009-08
Plain-language summary
The purpose of this study is to determine whether intravenous immunoglobulins are effective in the treatment of complex-regional pain syndrome.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* CRPS 1 (according to the IASP criteria) between 6 weeks and 6 months after diagnosis
* skin temperature of the affected side equal or higher than on non-affected side
* no change of the analgetic or co-analgetic medication within the last 10 days
Exclusion Criteria:
* Immunosuppressive or immunomodulatory treatment within the last three months
* CRPS previously treated with sympathetic block, lidocaine patch, local DMSO, spinal cord stimulation, intrathecal drug administration
* Known immune-mediated neuropathy (CIDP, MMN, MADSAM)
* Selective IgA-deficiency
* Severe heart disease
* Tumour disease in the last 5 years
* Allergy against Gamunex 10%
* Chronic renal disease Vaccination with live vaccine within the last three months
* Member of another clinical trial within the last 3 months